HEALTHCARE

Beersheva's second hospital will be operated by Sheba Medical Center, and is due to open by 2028.

Richard Francis's compensation cost $25.7 million in 2023, although that includes incentives for him to join the company.

RevitalVision's products treat certain eye conditions by retraining the brain.

InSightec and Gamida-Cell were two great hopes of Israel's biomed industry, but the one faces an uncertain future while Elbit Medical has relinquished the other in a debt settlement.

The Israeli stem cell company will lay off 25% of its workforce and close its Jerusalem development center.

Israeli company Mapi could receive milestone payments from Viatris worth tens of millions of dollars, and royalties from sales, if the product ever reaches the market.

The Israeli company's share price jumped 150% on the news.

The Israeli company has developed a platform to enhance care outcomes and reduce overheads for both employers and employees.

Together with Harvard and MIT scientists, Micha Breakstone founded Somite.ai, which combines stem cell and AI techniques to develop new therapies.

The US magazine has named Sheba Medical Center in Tel Hashomer as the world's ninth best hospital.

The product can measure brain and heart activity and many other physiological signs.

Richard Francis is confident that Teva's share price will continue to rise but says it will take many years to get back to its 2015 peak.

The Israeli biotech stem cell company will delist from the TASE.

The company, which has developed and marketings a helmet for deep transcranial magnetic stimulation, has seen its share price rise 230% in the past year.

The Israeli pharmaceutical company had 36,472 employees at the end of 2023, up 3.8% from 2022, as it returned to growth.

Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to transurethral resection of bladder tumor.

Former Israeli Prime Minister Naftali Bennett has joined the board of Remepy, which is pioneering hybrid drugs that include therapeutic applications that enhance the drug effect.

A survey finds young Israeli researchers struggling to secure vital international collaboration, and that more wish to leave the country.

Data from "The Wall Street Journal" show that just three months ago the analysts' consensus on Teva's share price was neutral, whereas today it is positive.

After six years as chair of the Israel Innovation Authority, Dr. Ami Appelbaum champions its independence from political control, and describes his fears and hopes for Israel's tech sector.

A study at the WVU Rockefeller Neuroscience Institute found that Insightec's focused ultrasound device enabled a drug to cross the blood-brain barrier rapidly.

At the end of 2023, Israeli insurance and finance group The Phoenix Holdings' stake in Teva was 5.4%.

The Israeli pharmaceutical company is to divest its active-pharmaceutical ingredient business in the small-molecule industry.

Israel's life sciences and medical devices market has begun 2024 out of step with the international mood because of the war.

Compared with traditional methods of coffee production, Pluri’s cell-based coffee is estimated to cut water usage by 98%.

The US investment bank has also raised its target price for the Israeli pharmaceutical company's share to $14.

India's Sun Pharmaceutical Industries will pay $43 per share for the 21.5% of Taro that it does not already own. Taro employs 1,550 people in Israel.

Aleph Farms still has to receive approval for its production line with procedures expected to be completed in the coming months so that the products will be available by mid-2024.

The Council for Higher Education is due to publish revised conditions for setting up a medical school, behind which is a clash between Reichman University and the existing schools.

The Israeli pharmaceutical company's share price has risen 50% over the past six months but is still 80% down on its peak in 2015.